Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 8-K (Current Report)
Date: November 14, 2014
Event: Entry into a Material Definitive Agreement (364-Day Bridge Term Loan) to support the pending acquisition of CareFusion Corporation.
Key Financial Metrics and Terms
- Bridge Loan Capacity: $9.1 billion principal amount available in a single draw.
- Loan Term: 364 days (due and payable within one year of borrowing).
- Interest Rate: Eurodollar rate plus 100–250 basis points OR Base rate plus 0–150 basis points (margin dependent on credit ratings and days outstanding).
- Security Status: Unsecured.
- Financial Covenants:
- EBITDA to Interest Expense ratio: Minimum 5.00:1.00.
- Debt to EBITDA ratio: Maximum 4.75:1.00 (post-closing).
- Administrative Agent: Goldman Sachs Bank USA.
Material Changes and Strategic Intent
BD entered into the Bridge Loan Agreement to fund a portion of the cash consideration for the acquisition of CareFusion Corporation and associated transaction costs. The filing indicates that BD intends to use this bridge financing only if permanent financing (senior notes, term loan, or combination) cannot be obtained. The agreement is contingent upon the consummation of the Merger and the absence of undisclosed material adverse effects at CareFusion since June 30, 2014.
Outlook, Risks, and Contingencies
- Financing Contingency: There is no assurance that permanent financing will be obtained; the bridge loan is a fallback mechanism.
- Transaction Risks: Risks include failure to obtain regulatory approvals, delays in closing, integration challenges, and the possibility that anticipated synergies may not be realized.
- Default Triggers: The loan is subject to acceleration upon events of default, including cross-defaults on indebtedness exceeding $200 million, failure to pay other indebtedness of at least $25 million, change of control, or entry of a judgment of $25 million or more.
- Forward-Looking Statements: Management estimates regarding the transaction's benefits and timing are subject to significant uncertainties, including healthcare funding changes and competition.
Investor Verification Checklist
- Verify the status of the permanent financing (senior notes or term loan) BD expects to replace the bridge loan.
- Confirm the receipt of all necessary regulatory approvals for the CareFusion merger.
- Review the definitive proxy statement/prospectus (Form S-4) for detailed terms of the merger and potential conflicts of interest.
- Monitor BD's credit ratings, as they directly impact the interest rate margin on the bridge loan.
- Assess the impact of the Debt to EBITDA covenant (4.75:1.00) on BD's future capital flexibility post-merger.